ArticleThe Australian & New Zealand journal of obstetrics & gynaecology2026
Association of Intralipid Infusions With Birth Outcomes and First-Trimester Placental Biomarkers in Frozen Embryo Transfer Cycles: A Retrospective Cohort Study.
Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntralipid is used as an adjunctive therapy in assisted reproductive technology (ART), but data regarding pregnancy outcomes and early placental biomarkers are limited.
aimsTo evaluate the association between Intralipid exposure during frozen embryo transfer (FET) cycles and pregnancy outcomes, birthweight and first-trimester placental biomarkers. MATERIALS AND
methodsThis retrospective cohort study included 729 women undergoing FET cycles resulting in delivery beyond 20 weeks at a private assisted reproduction clinic between 2017 and 2023. Outcomes were compared between women receiving intravenous Intralipid (n = 136) and those not receiving Intralipid (n = 593). Multivariable analyses adjusted for maternal age, body mass index, parity, plurality, foetal sex, cycle type, intracytoplasmic sperm injection (ICSI) use and preimplantation genetic testing for aneuploidy (PGT-A) status.
resultsIndividual pregnancy outcomes, including preterm birth, hypertensive disorders of pregnancy, gestational diabetes, foetal growth restriction, congenital anomalies and stillbirth, did not differ significantly between groups. Intralipid exposure was not independently associated with the composite adverse pregnancy outcome after adjustment (adjusted OR 2.08, 95% CI 0.73-5.96; p = 0.171). Intralipid-exposed pregnancies had lower first-trimester PAPP-A MoM values after adjustment (adjusted geometric mean ratio 0.86, 95% CI 0.76-0.98; p = 0.021), whereas PlGF and free β-hCG concentrations did not differ significantly. Lower PAPP-A concentrations were not associated with birthweight z-scores.
conclusionsIntralipid exposure was not independently associated with adverse pregnancy outcomes after adjustment. Pregnancies exposed to Intralipid had lower first-trimester PAPP-A measures without corresponding differences in other placental biomarkers or birthweight z-scores. Linkage of the Australia and New Zealand Assisted Reproduction Database with perinatal outcome registries, with routine capture of adjunctive ART therapies, would support more comprehensive maternal and neonatal safety evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.